Nature14y
The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival
These biological responses to AZD1480 are associated with concomitant inhibition of phosphorylation of JAK2, STAT3 and MAPK signaling proteins. In addition, there is inhibition of expression of ...
Medical Xpress on MSN7d
Could an arthritis drug unlock lasting relief from epilepsy and seizures? UW–Madison researchers see promising results in mice
A drug typically prescribed for arthritis halts brain-damaging seizures in mice that have a condition like epilepsy, according to researchers at the University of Wisconsin–Madison. If the drug proves ...
Bio-Path Holdings Announces Pre-Clinical Results Signaling Increased Potential for BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients
Updated results from BP1001-A obesity and Type 2 diabetes testing from the second stage of pre-clinical testing are as follows: Previously, Bio-Path reported BP1001-A increased insulin sensitivity in ...
Hosted on MSN1mon
Bio-Path Holdings expands global patent portfolio
The U.S. Patent and Trademark Office granted a Notice of Allowance for a patent titled "P-ethoxy nucleic acids for STAT3 inhibition," and the New Zealand Intellectual Property Office awarded ...
Purple Biotech Granted New U.S. Patent for NT219 in Combination with EGFR Antibody Therapy, Enhancing Global IP Protection in Major Markets
NT219 in combination with EGFR antibody cetuximab (Erbitux) is currently entering a Phase 2 study for head and neck cancer ...